Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index; 21 of the 30 sources its claims cite were checked for support.
Abstract
Metabolic dysfunction–associated steatotic liver disease (MASLD) is shaped by metabolic injury and tissue mechanics. This study investigated whether liver stiffening occurs early in MASLD and how extracellular matrix (ECM) mechanics interact with lipid droplet (LD) overload to promote inflammation, fibrogenesis, and lipid dysmetabolism. Clinical data, mouse models, and in vitro experiments are integrated. Liver stiffness shifted modestly with steatosis but increased substantially in the presence of inflammation. In a diet‐induced mouse model, liver stiffness increased before overt fibrosis. In cultured hepatocytes, stiff matrices combined with free fatty acid (FFA) induced steatosis synergistically amplified pro‐inflammatory and pro‐fibrotic signals, accompanied by cytoskeletal remodeling and nuclear deformation. YAP acted as a central mechanosensitive amplifier: stiffness drove YAP nuclear localization, and YAP knockdown blunted cytokine induction and fibrogenic gene expression under stiff + FFA conditions. Stiffness and LD overload jointly promoted lipogenesis and impaired lipophagy via YAP. Piezo1 is upregulated by stiff + FFA; its inhibition reduced Ca 2 ⁺ influx and prevented YAP activation. Collectively, early liver stiffening, together with LD‐derived intracellular stress, engages a Piezo1–YAP axis that amplifies inflammation, fibrogenesis, and disordered lipid metabolism, consistent with a proposed feed‐forward loop mechanism accelerating MASLD progression.
Overview
CoChat Summary
## TL;DR
This study argues that liver stiffness increases early in MASLD, before overt fibrosis, and that stiffness works with lipid droplet overload to drive inflammation, fibrogenesis, and disordered lipid metabolism. It identifies a Piezo1–YAP mechanotransduction axis in hepatocytes as the key pathway linking extracellular stiffness and intracellular lipid stress.
## Key findings
- In a clinical cohort of 24,449 people, liver stiffness measurement (LSM) increased modestly with CAP-defined steatosis severity; in a second cohort of 1,315, people with elevated aminotransferases had higher CAP and LSM than enzyme-normal counterparts.
- AFM on 5 surgical liver specimens showed graded increases in Young’s modulus from healthy liver to simple steatosis, steatohepatitis, and advanced fibrosis.
- In an MCD-diet mouse model, liver stiffness increased with disease progression and rose before overt fibrosis; storage modulus correlated strongly with NAS, LD burden, AST/ALT, and circulating cytokines.
- In hepatocyte models, stiff + FFA conditions most strongly increased inflammatory cytokines (IL-6, IL-1β, TNF-α), fibrogenic mediators (TGF-β1, IHH), YAP nuclear localization, lipogenesis, and impaired lipophagy; Piezo1 was the most strongly induced mechanosensitive channel and its inhibition reduced Ca²⁺ influx and YAP activation.
## Methods
- Integrated two clinical cohorts, an MCD-diet mouse model, and in vitro hepatocyte experiments on tunable polyacrylamide hydrogels; clinical LSM/CAP were measured by FibroScan.
- Compared soft (~0.5 kPa) versus stiff (~20 kPa) matrices, with or without FFA (OA:PA = 2:1, 0.5 mM), in HepG2 and THLE-2 cells.
- Main analyses included AFM, rheometry, histology/IHC/IF, qRT-PCR, transcriptomic profiling, GSEA/GO/KEGG, correlation analyses, and YAP or Piezo1 perturbation (siRNA, GsMTx4).
## Limitations
- The paper states that advanced fibrosis (F ≥ 3) could not be fully excluded in the clinical cohorts because there were no protocol liver biopsies.
- It also states that the MCD diet lacks key features of human MASLD, such as obesity and insulin resistance.
- The discussion notes that AFM-derived Young’s moduli are apparent comparative values, not absolute material properties, because the Hertz model assumes linear elasticity and homogeneity.
- The text makes evident that the Piezo1 inhibitor GsMTx4 is not fully selective, so the specificity of Piezo1-mediated effects is not definitively proven by pharmacology alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
11 Valid · 2 Not valid · 2 Not checked · 133 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“lipid droplets (LDs), once regarded as inert metabolic depots, generate surface tension and rigidity sufficient to compress nuclei and disrupt cytoskeletal architecture [21]”
§ Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction > Introduction
What the sources say
- Disputedcites [21] A. Romanauska and A. Köhler, “ Lipid Saturation Controls Nuclear Envelope Function,” Nature Cell Biology 25, no. 9 (2023): 1290– 1302, 10.1038/s41556-023-01207-8. 37591950 PMC10495262 sourceExperimental — accuracy not yet measured
The Results section, “Lipid droplets preserve NPC and NE integrity” (page unavailable), says that increasing lipid droplets reduced abnormal nuclear-envelope shapes and helped preserve nuclear integrity—the opposite of attributing nuclear deformation to droplets. The paper attributes membrane rigidity to excess saturated lipids, not droplet surface tension, and does not report droplet-driven cytoskeletal disruption. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“While the MCD diet lacks key metabolic features of human MASLD, such as obesity and insulin resistance [30, 31, 32]”
§ Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction > Discussion
What the sources say
- Could not verifycites [30] H.‐S. Park, J.‐W. Song, J.‐H. Park, et al., “ TXNIP/VDUP1 Attenuates Steatohepatitis via Autophagy and Fatty Acid Oxidation,” Autophagy 17, no. 9 (2021): 2549– 2564, 10.1080/15548627.2020.1834711. 33190588 PMC8496541 sourceExperimental — accuracy not yet measured
Our copy of Park et al. (Autophagy, 2021) uses the MCD diet purely as a steatohepatitis model and never comments on its metabolic shortcomings relative to human MASLD. Repeated searches for statements about obesity, insulin resistance or model limitations returned only the Results passage noting 'The body weights were similar between WT and txnip-KO mice after MCD diet feeding' (a genotype comparison, not a claim that the MCD diet fails to produce obesity) and the observation that 'In MCD diet-fed mice, serum FFA levels were also significantly elevated compared with controls' (Results). No passage addresses insulin resistance or the absence of obese/metabolic-syndrome features, so the attributed point cannot be checked against this source. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [31] J. C. Bórquez, F. Díaz‐Castro, F. P. La Fuente, et al., “ Mitofusin‐2 Induced by Exercise Modifies Lipid Droplet‐mitochondria Communication, Promoting Fatty Acid Oxidation in Male Mice With NAFLD,” Metabolism 152 (2024): 155765, 10.1016/j.metabol.2023.155765. 38142958 source
- Supportedcites [32] M. A. Alshawsh, A. Alsalahi, S. A. Alshehade, et al., “ A Comparison of the Gene Expression Profiles of Non‐Alcoholic Fatty Liver Disease Between Animal Models of a High‐Fat Diet and Methionine‐Choline‐Deficient Diet,” Molecules (Basel, Switzerland) 27, no. 3 (2022): 858, 10.3390/molecules27030858. 35164140 PMC8839835 source
Section 2, “Challenges Encountered in NAFLD Animal Models” (page unavailable), says the HFD model develops insulin resistance whereas the MCD model shows lower levels. It also reports weight gain in HFD-fed animals but weight loss in MCD-fed animals, supporting the point that the MCD model does not reproduce obesity. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“accumulating evidence highlights extracellular matrix (ECM) remodeling and tissue mechanics as active determinants of hepatocyte behavior [12, 13, 14, 15, 16].”
§ Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction > Introduction
What the sources say
- Supportedcites [12] B. Wu, D.‐A. Liu, L. Guan, et al., “ Stiff Matrix Induces Exosome Secretion to Promote Tumour Growth,” Nature Cell Biology 25, no. 3 (2023): 415– 424, 10.1038/s41556-023-01092-1. 36797475 PMC10351222 source
The Results section (“Matrix stiffening promotes exosome secretion”; page not provided) reports that primary human hepatocytes cultured on stiff matrix released more exosomes than those on soft matrix. This directly supports the broad point that ECM mechanics can affect hepatocyte behavior. (LLM, conf=0.91)
- Partly supportedcites [13] W. Zhang, W. Wu, N. Zhang, et al., “ Hepatic Stellate Cell‐derived Microfibrillar‐associated Protein 2 Prevents Liver Fibrosis by Regulating Extracellular Matrix and Inflammation,” Theranostics 15, no. 9 (2025): 4033– 4053, 10.7150/thno.109771. 40213670 PMC11980660 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links ECM accumulation in liver fibrosis to increased stiffness and viscoelasticity. The Results (page unavailable) link ECM remodeling to focal-adhesion signaling in hepatic stellate cells. These passages support an active role for ECM remodeling and tissue mechanics in liver disease, but they do not establish them as determinants of hepatocyte behavior. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [14] T. Zuo, Q. Xie, J. Liu, et al., “ Macrophage‐Derived Cathepsin S Remodels the Extracellular Matrix to Promote Liver Fibrogenesis,” Gastroenterology 165, no. 3 (2023): 746– 761.e16, 10.1053/j.gastro.2023.05.039. 37263311 source
- Partly supportedcites [15] W. Fan, K. Adebowale, L. Váncza, et al., “ Matrix Viscoelasticity Promotes Liver Cancer Progression in the Pre‐Cirrhotic Liver,” Nature 626 (2024): 635– 642, 10.1038/s41586-023-06991-9. 38297127 PMC10866704 sourceExperimental — accuracy not yet measured
The Abstract and “Matrix viscoelasticity activates YAP through TNS1” section show that ECM remodeling changes liver matrix mechanics and that increased viscoelasticity promotes HCC-cell proliferation and invasion. The claim extends this finding to hepatocyte behavior generally, whereas the reported cell-behavior experiments concern cancer cells. (LLM, conf=0.83)
- Partly supportedcites [16] Y. Zheng, R. Zhou, J. Cai, et al., “ Matrix Stiffness Triggers Lipid Metabolic Cross‐Talk Between Tumor and Stromal Cells to Mediate Bevacizumab Resistance in Colorectal Cancer Liver Metastases,” Cancer Research 83, no. 21 (2023): 3577– 3592, 10.1158/0008-5472.Can-23-0025. 37610655 PMC10618741 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says ECM remodeling and tumor-associated stiffness affect hepatic stellate cells in liver metastases. The Results section on matrix stiffness and lipolysis likewise reports responses in hepatic stellate cells, not hepatocytes. The source supports a role for tissue mechanics in cell behavior, but not the claim’s specific attribution to hepatocyte behavior. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Because GsMTx4 is not entirely specific for Piezo1 [42, 43]”
§ Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction > Discussion
What the sources say
- Could not verifycites [42] Z. Xu, S. Xu, X. Liu, et al., “ Deficiency of Epithelial PIEZO1 Alleviates Liver Steatosis Induced by High‐Fat Diet in Mice,” International Journal of Biological Sciences 21, no. 2 (2025): 745– 757, 10.7150/ijbs.102906. 39781454 PMC11705646 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes PIEZO1 as a non-selective cation channel, but that describes the channel, not the specificity of GsMTx4. Searches for GsMTx4 and inhibitor specificity found no passage in our copy addressing the claim. (LLM, conf=0.72)
- Could not verifycites [43] N. Wei, L. Du, Z. Xiao, et al., “ Portal hypertension contributes to ascites formation via the Piezo1−nuclear factor kappa‐B−aquaporin1 pathway in liver cirrhosis,” Experimental & Molecular Medicine 57 (2025): 2305– 2316, 10.1038/s12276-025-01554-6. 41034523 PMC12586457 sourceExperimental — accuracy not yet measured
The Introduction and Results discuss Piezo1 and experiments using endothelial cell-specific Piezo1 deletion, but do not address whether GsMTx4 is specific for Piezo1. Searches for “GsMTx4” and for inhibitor specificity found no passage on that point in our copy. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“our results extend current MASLD frameworks, traditionally centered on metabolic dysregulation and inflammation, into an integrated mechanical–metabolic–inflammatory axis [44, 45, 46, 47, 48]”
§ Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction > Discussion
What the sources say
- Not checked — no full text of the sourcecites [44] N. A. Cumpian, J. A. Gutierrez, W. Wu, and S. Saab, “ Targeting MASLD and MASH in the US Hispanic/Latino Population: A Review,” JAMA Internal Medicine 185, no. 11 (2025): 1376– 1386, 10.1001/jamainternmed.2025.4769. 40982275 source
- Supportedcites [45] J. P. Rose, D. A. Morgan, A. I. Sullivan, et al., “ FGF21 reverses MASH Through Coordinated Actions on the CNS and Liver,” Cell Metabolism 37, no. 7 (2025): 1515– 1529, 10.1016/j.cmet.2025.04.014. 40367940 PMC12409791 source
The Introduction describes MASLD in terms of metabolic risk factors and hepatic lipid accumulation, and describes progression to MASH as involving inflammation and fibrosis. This supports the background framework for which the source is cited; the proposed mechanical–metabolic–inflammatory extension is explicitly the citing authors’ own result, not a finding attributed to this paper. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [46] W. Xie, J. Gan, X. Zhou, et al., “ Myocardial Infarction Accelerates the Progression of MASH by Triggering Immunoinflammatory Response and Induction of Periosti,” Cell metabolism 36, no. 6 (2024): 1269– 1286.e9, 10.1016/j.cmet.2024.04.020. 38838640 source
- Supportedcites [47] Q. Wu, Y. Yang, S. Lin, D. A. Geller, and Y. Yan, “ The Microenvironment in the Development of MASLD‐MASH‐HCC and Associated Therapeutic in MASH‐HCC,” Frontiers in Immunology 16 (2025): 1569915, 10.3389/fimmu.2025.1569915. 40370443 PMC12074932 source
The citation supports the background description of MASLD frameworks, not the citing authors’ claim about what their own results add. The Introduction identifies metabolic disorders as contributors to MASLD and inflammation as a feature of MASH; the Hepatocytes section describes how lipid accumulation triggers inflammatory responses. The source need not establish the proposed mechanical–metabolic–inflammatory axis. (LLM, conf=0.90)
- Supportedcites [48] Z. M. Younossi, S. Zelber‐Sagi, J. V. Lazarus, et al., “ Global Consensus Recommendations for Metabolic Dysfunction‐Associated Steatotic Liver Disease and Steatohepatitis,” Gastroenterology 169, no. 5 (2025): 1017– 1032.e2, 10.1053/j.gastro.2025.02.044. 40222485 source
The introduction (p. 2) describes MASLD in terms of metabolic dysfunction and characterizes its progressive form, MASH, by liver inflammation. That supports the background framework for which this source is cited. The mechanical–metabolic–inflammatory axis is explicitly presented as the citing authors’ interpretation of their own results, not as a finding attributed to this source. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
69 more claims
Create a free account to see all 148 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 57
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both cases, lipid metabolism as well as pro‐inflammatory and pro‐fibrotic transcriptional programmes are regulated by YAP/TAZ proteins [51, 52].”
From Mechanical stiffness orchestrates distinct regulation of MRTFs and YAP / TAZ transcriptional cofactors in hepatocytes (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Gluconeogenesis has been described to be regulated by YAP in the liver [32], and MRTFs have been linked to glucose metabolism as well [51, 55].”
From Mechanical stiffness orchestrates distinct regulation of MRTFs and YAP / TAZ transcriptional cofactors in hepatocytes (2026) · cites this paper as [51]
Experimental — accuracy not yet measured
Citations
Cites
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E., Anstee, Q. M., Sheridan, D., Guha, I. N., Cobbold, J. F., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,410
Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275
Epidemiology of metabolic dysfunction-associated steatotic liver disease
Younossi, Z. M., Kalligeros, M., & Henry, L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0431 · Cited by 960
Newsome, P. N., Sasso, M., Deeks, J. J., Paredes, A., Boursier, J., Chan, W.-K., Yilmaz, Y., Czernichow, S., Zheng, M.-H., Wong, V. W.-S., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30383-8 · Cited by 800
Current status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781 · cited 1×
“It is estimated to affect more than one-third of the adult population and is increasingly recognized as a major driver of liver-related morbidity, mortality, and healthcare burden [ 1–4 ].”
Du, K., Hyun, J., Premont, R. T., Choi, S. S., Michelotti, G. A., Swiderska-Syn, M., Dalton, G. D., Thelen, E., Rizi, B. S., Jung, Y., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.022 · Cited by 339
Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., Teng, M., Syn, N., Lim, G., Yong, J. N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00078-x · Cited by 307
Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver
Fan, W., Adebowale, K., Váncza, L., Li, Y., Rabbi, M. F., Kunimoto, K., Chen, D., Mozes, G., Chiu, D. K.-C., Li, Y., et al. (2024) · Nature · doi:10.1038/s41586-023-06991-9 · Cited by 263 · cited 2×
“Inhibition of AGE formation mitigates these effects [ 15 ].”
Research works printed but not linked: 1
- I. L. Ivanovska, M. P. Tobin, T. Bai, L. J. Dooling, and D. E. Discher, “ Small Lipid Droplets Are Rigid Enough to Indent a Nucleus, Dilute the Lamina, and Cause Rupture,” Journal of Cell Biology 222, no. 8 (2023): 202208123, 10.1083/jcb.202208123. PMC10202833 37212777 · doi:10.1083/jcb.202208123
Cited by
Al-Mughalles, A. S., Ma, J., Ma, H., Zhang, C., Xiao, H., Ma, X., Zhang, Q., Jia, C., Han, H., Ding, B., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02997-8 · Cited by 4
Self-citationEl‐Moaty, H. I. A., Saber, S., Hamad, R. S., Elmorsy, E. A., Farrag, A. A. M., Cavalu, S. D., Eissa, H., El-kott, A. F., Negm, S., AlShehri, M. A., et al. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103375 · Cited by 2
Chen, H., Wang, Q., Yang, K., Lian, Q., Peng, X., Gong, Z., Zhao, X., Wu, Y., Tao, T., Xu, S., et al. (2026) · Advanced Science · doi:10.1002/advs.202515847 · Cited by 2
Xu, S., Jiang, Z., Zhang, Q., & Guo, J. Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1879836 · Cited by 3
Kosaka, M., Okamoto‐Uchida, Y., Hirose, H., Nagaoka, Y., Miyamura, N., Kanai, A., Hatakeyama, D., Nakagawa, M., Nishio, M., Maehama, T., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10882-w · Cited by 1
- Self-citation
Torres‐Ortiz, B. S., Pérez‐Calixto, D., Carretero‐Ortega, J., Guzman‐López, A. G., Pinto‐Dueñas, D. C., Hernández‐Juárez, M., Jiménez‐Escobar, A., Rodríguez‐Hernández, A., Díaz‐Bello, B., Serna‐Márquez, N., et al. (2026) · The FEBS Journal · doi:10.1111/febs.70570
Mechanobiology of inflammation: Pulling the strings of innate immunity
Maniak, M. K., Jenkins, S. J., & Hansen, C. G. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20252269 · Cited by 5
The mechanics of liver regeneration
Maeso‐Díaz, R., & Diehl, A. M. (2026) · Science · doi:10.1126/science.aei7784
Yuan, X., Chang, L., Zhuang, Z., Chen, P., Xiong, Z., Lu, J., & Zhang, Y. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70832
Zhong, M.-Y., Yang, S.-Y., Xu, W.-H., Zhang, Y.-K., & Zhao, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00544-y
Zhu, B., Wan, J., Zhang, X., Yan, J., Chen, X. D., Guan, X., Ren, Q., Yang, T., Wu, D., Guo, Q., et al. (2026) · Advanced Science · doi:10.1002/advs.76173
Ai, B., & Chong, X. (2026) · Cells · doi:10.3390/cells15141272
Metadata
- Authors
- Ma, J., Xie, N., Wang, Z., Liang, X., Han, Y., Zhao, Q., Wang, M., Lu, H., Kou, W., Alazawi, W., Wang, J., Li, L., Liu, N., Liu, N., Shi, H., & Xu, F.
- Affiliations
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Nanjing University of Aeronautics and Astronautics (CN)
- Xi'an Jiaotong University (CN)
- Queen Mary University of London (GB)
- Department of Gastrointestinal Surgery Hainan General Hospital Hainan Affiliated Hospital of Hainan Medical University Haikou P. R. China
- Department of Gastroenterology Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University) Haikou P. R. China
- Corresponding author
- Shi, Haitao
- Xu, Feng
- ORCID
- Xu, Feng
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2026-01-04
- Volume
- 13
- Issue
- 19
- Pages
- e19109-e19109
- ISSN
- 2198-3844 (ISSN-L)
- PMC
- PMC13045404
- OpenAlex
- W7118166457
- Cited by
- 14
- References
- 43
- Citations by year
- 2026: 14
- FWCI
- 48.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Locations
- Advanced Science (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (12432015,82560549)
- Key Research and Development Projects of Shaanxi Province (2023GXLH‐033)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, liver stiffness, mechanotransduction, Piezo1, YAP, extracellular matrix mechanics, liver inflammation, liver fibrosis
- MeSH terms
- YAP-Signaling Proteins, Animals, Disease Models, Animal, Fatty Liver, Humans, Inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.